Besides mutation, hypermethylation of the promoter of BRCA1, which is observed in approximately 10–15% of sporadic ovarian carcinomas, and more especially in serous carcinomas, could also predict response to PARP inhibitors [37]. The gene discussed is BRCA1; the disease is serous adenocarcinoma.